Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

X4 Pharmaceuticals (XFOR) Accumulated Depreciation & Amortization (2018 - 2025)

X4 Pharmaceuticals' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 60.43% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 60.43%, while the annual FY2025 figure was $1.3 million, 60.43% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.3 million in Q4 2025 per XFOR's latest filing, up from $831000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.3 million in Q4 2025 to a low of $62000.0 in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $414947.4, with a median of $367000.0 recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 51.18% in 2024, then soared 667.74% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $499000.0 in 2021, then grew by 2.81% to $513000.0 in 2022, then dropped by 18.32% to $419000.0 in 2023, then skyrocketed by 89.98% to $796000.0 in 2024, then soared by 60.43% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Accumulated Depreciation & Amortization are $1.3 million (Q4 2025), $831000.0 (Q2 2025), and $476000.0 (Q1 2025).